首页> 外文期刊>International Journal of General Medicine >Benefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertension
【24h】

Benefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertension

机译:慢性输血对血红蛋白E /β地中海贫血合并肺动脉高压的益处

获取原文
           

摘要

Objective: The aim of the research reported here was to compare pulmonary artery systolic pressure (PASP) and 6-minute walk distance after 1 year of follow-up in hemoglobin E/β thalassemia (E/β-Thal) with pulmonary arterial hypertension (PAH) patients who received chronic blood transfusions versus those who received occasional transfusions. Methods: A nonrandomized clinical trial was conducted at the Hematological Outpatient Clinic of Chiang Rai Hospital, Thailand. All adult cases of E/β-Thal with PAH (defined as PASP >35 mmHg by Doppler echocardiography) were evaluated and followed for the next 12 months. The patients were classified into two groups by patient preference. Group 1 patients received chronic blood transfusions – one to two units of leukocyte-poor packed red cells every 2–4 weeks – over 1 year to maintain pre-transfusion hemoglobin levels of ≥7.0 g/dL. Group 2 patients received occasional transfusions over the course of 1 year, with more than 4 weeks between transfusions. All patients were treated with iron chelation when serum ferritin levels were ≥1,000 μg/dL. PASP and the 6-minute walk distance were evaluated at baseline and at 6 and 12 months. Propensity score adjustment was used to control for confounding by indication and contraindication. Multivariable regression analysis was used to evaluate the effects of chronic blood transfusion. Results: There were 16 (53.3%) patients in Group 1 and 14 (46.7%) in Group 2. At 12 months, patients in Group 1 had a greater reduction in PASP than those in Group 1 (adjusted mean difference, ?16.83; 95% confidence interval, ?26.35 to ?7.32; P=0.001). The 6-minute walk distance at 12 months in Group 1 patients was greater than that in Group 2 patients (adjusted mean difference, 46.55; 95% confidence interval, 18.08 to 75.02; P=0.001). Conclusion: This study found evidence that chronic blood transfusions may have beneficial effects in PAH in thalassemia patients over 1 year.
机译:目的:本研究报告的目的是比较血红蛋白E /β地中海贫血(E /β-Thal)与肺动脉高压(1 / s)随访1年后的肺动脉收缩压(PASP)和6分钟步行距离PAH)接受慢性输血的患者与偶尔接受输血的患者。方法:在泰国清莱医院血液科门诊进行了一项非随机临床试验。对所有成人多发性PAH的E /β-Thal病例(多普勒超声心动图定义为PASP> 35 mmHg)进行评估,并随访接下来的12个月。根据患者喜好将患者分为两组。第1组患者接受了长期输血-每2-4周每1至2个贫白细胞装满红细胞-维持输血前血红蛋白水平≥7.0 g / dL。第2组患者在1年的时间里偶尔接受输血,两次输血之间间隔4周以上。当血清铁蛋白水平≥1,000μg/ dL时,所有患者均接受铁螯合治疗。在基线,6个月和12个月时评估PASP和6分钟的步行距离。倾向得分调整用于通过适应症和禁忌症控制混杂。多变量回归分析用于评估慢性输血的效果。结果:第1组患者16例(53.3%),第2组14例(46.7%)。在第12个月时,第1组患者的PASP降低量大于第1组(调整后平均差异为±16.83; 95%置信区间(?26.35至?7.32; P = 0.001)。第1组患者在12个月时的6分钟步行距离大于第2组患者(调整后平均差异为46.55; 95%置信区间为18.08至75.02; P = 0.001)。结论:本研究发现证据表明,长期输血对地中海贫血患者1年以上的PAH可能具有有益的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号